🇺🇸 FDA
Company

FATE

FATE THERAPEUTICS INC

FATE biotech USA

Quick answer

FATE is a biotech company (FATE) headquartered in SAN DIEGO, CA, USA with 23 tracked pipeline programs.

Pipeline (23)

project

FT819

Lupus Nephritis

Phase 2 · mab · active

1 trials project

ProHema-CB

Hematologic Malignancies

Phase 2 · mab · terminated

1 trials project

ProTmune

Hematologic Malignancies

Phase 2 · mab · completed

1 trials project

Biological: ProHema-CB

Hematologic Malignancies

Phase 1 · mab · terminated

1 trials project

FATE-NK100

HER2 Positive Gastric Cancer

Phase 1 · small_molecule · completed

1 trials project

FT500

Advanced Solid Tumors

Phase 1 · small_molecule · completed

1 trials project

FT516

Solid Tumor, Adult

Phase 1 · small_molecule · terminated

1 trials project

FT516

Acute Myelogenous Leukemia

Phase 1 · small_molecule · terminated

1 trials project

FT522

Relapsed/Refractory B-Cell Lymphoma

Phase 1 · small_molecule · completed

1 trials project

FT536

Non Small Cell Lung Cancer

Phase 1 · small_molecule · terminated

1 trials project

FT536

Astrocytoma

Phase 1 · mab · active

1 trials project

FT538

Acute Myeloid Leukemia

Phase 1 · small_molecule · terminated

1 trials project

FT538

Solid Tumor, Adult

Phase 1 · small_molecule · terminated

1 trials project

FT576 (Allogenic CAR NK cells with BCMA expression)

Multiple Myeloma

Phase 1 · small_molecule · completed

1 trials project

FT596

Diffuse Large B Cell Lymphoma

Phase 1 · small_molecule · terminated

1 trials project

FT596

Lymphoma, B-Cell

Phase 1 · small_molecule · terminated

1 trials project

FT819

Lymphoma, B-Cell

Phase 1 · small_molecule · active

1 trials project

FT819

Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)

Phase 1 · small_molecule · active

1 trials project

FT825

Advanced Solid Tumor

Phase 1 · small_molecule · active

1 trials project

FT836

Non-Small Cell Lung Cancer

Phase 1 · small_molecule · active

1 trials project

Fludarabine

Hematologic Malignancies

Phase 1 · small_molecule · completed

1 trials project

ProHema-CB Transplant

Metabolic Disorders

Phase 1 · mab · terminated

1 trials project

Single FT1050 treated UCB unit

Non-Hodgkin's Lymphoma (NHL)

Phase 1 · mab · completed

1 trials

Patents (8)

patent

US 12419870

Compositions and methods for immune cell modulation in adoptive immunotherapies

Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12410403

Methods and compositions for inducing hematopoietic cell differentiation

Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12398373

Enhanced immune effector cells and use thereof

Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12385012

Methods and compositions for inducing hematopoietic cell differentiation

Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12281329

Compositions and methods for immune cell modulation in adoptive immunotherapies

Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12275955

Combining iPSC derived effector cell types for immunotherapy use

Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12264322

Minimal volume reprogramming of mononuclear cells

Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12247226

Cellular reprogramming using temporal and transient plasmid vector expression sy

Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)